Cargando…
Protective effects of metformin in various cardiovascular diseases: Clinical evidence and AMPK‐dependent mechanisms
Metformin, a well‐known AMPK agonist, has been widely used as the first‐line drug for treating type 2 diabetes. There had been a significant concern regarding the use of metformin in people with cardiovascular diseases (CVDs) due to its potential lactic acidosis side effect. Currently growing clinic...
Autores principales: | Bu, Yizhi, Peng, Mei, Tang, Xinyi, Xu, Xu, Wu, Yifeng, Chen, Alex F., Yang, Xiaoping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549498/ https://www.ncbi.nlm.nih.gov/pubmed/36052760 http://dx.doi.org/10.1111/jcmm.17519 |
Ejemplares similares
-
Metformin regulates myoblast differentiation through an AMPK-dependent mechanism
por: Maniscalco, Eleonora, et al.
Publicado: (2023) -
Metformin selectively dampens the acute inflammatory response through an AMPK-dependent mechanism
por: Postler, Thomas S., et al.
Publicado: (2021) -
AMPK-Dependent YAP Inhibition Mediates the Protective Effect of Metformin against Obesity-Associated Endothelial Dysfunction and Inflammation
por: Kang, Lijing, et al.
Publicado: (2023) -
Metformin suppresses adipogenesis through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms
por: Chen, Suet Ching, et al.
Publicado: (2017) -
Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk
por: Peng, Mei, et al.
Publicado: (2016)